Last update May 25, 2018

G03CA09

Compatible

Safe substance and/or breastfeeding is the best option.

Estrogen derived from estradiol with trophic effects on vaginal mucosa. Indicated in vulvo-vaginal atrophy
Topical use once or twice daily.

Up to the last update date we did not find published data on your excretion in breastmilk.

The low plasma absorption through the vaginal mucosa (Santos 2010), less than 1% (AEMPS 2018), makes the passage of a significant amount to breast milk unlikely.
Negative absorption has been demonstrated through the infant foreskin (Salmon 2013) and the absence of hormonal systemic effects in women (Santos 2010, Wolff 1982) with the topical use of promestriene.

Non-hormonal lubricants (cream, jelly or ovules) are preferred agents for treatment of vaginal dryness due to hypo-estrogenic stimulation than those estrogenic-containing topical agents.

Alternatives

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

G03CA09 is Promestriene in ATC Code/s.

Is written in other languages:

Group

G03CA09 belongs to this group or family:

Tradenames

Main tradenames from several countries containing G03CA09 in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. Topica: < 1% %
Molecular weight 329 daltons

References

  1. AEMPS. Promestrieno (Colpotrofín). Ficha técnica. 2018 Full text (in our servers)
  2. Salmon D, Kassai B, Roussel L, Mouriquand P, Gérard C, Gorduza DB, Serre C, Falson F, Pivot C, Pirot F. Ex vivo absorption of promestriene from oil-in-water emulsion into infant foreskin. Int J Pharm. 2013 Abstract
  3. Santos I, Clissold S. Urogenital disorders associated with oestrogen deficiency: the role of promestriene as topical oestrogen therapy. Gynecol Endocrinol. 2010 Abstract
  4. Wolff JP, Cachelou R, Guéritée N. Absence of systemic hormonal effects in an oestradiol diether topically active on the vaginal mucosa. Maturitas. 1982 Abstract

Total visits

1,456

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by La Liga de la Leche de México of Mexico

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM